Evidence review
Compounded GLP-1 Vial Labels: What mg, mL and Units Mean
Understand the fields on a compounded GLP-1 vial label, identify unclear instructions and ask your pharmacist about concentration, units and beyond-use dates.
On this page
A compounded GLP-1 vial label should help you identify what the pharmacy dispensed. It should not leave you solving a dosing puzzle. If the vial, prescription directions and supplied syringe do not make sense together, pause and ask the dispensing pharmacist to reconcile them before using the medication.
This guide explains label vocabulary and questions to ask. It deliberately contains no dose conversions, syringe measurements or injection instructions. Sources were checked October 6, 2026; this is source-based editorial guidance, not a pharmacist's review of your prescription.
Four terms that answer different questions
Milligrams, abbreviated mg, describe the mass of a substance. Milliliters, abbreviated mL, describe a volume of liquid. A concentration expressed as mg/mL describes how much of the named ingredient is present per milliliter. The total volume printed on a vial describes its contents; it is not automatically the volume prescribed for one administration.
“Units” on a syringe do not, by themselves, identify how much semaglutide or tirzepatide is in it. The medication's concentration and the specific syringe matter. FDA has reported errors involving confusion among milligrams, milliliters and units, with some patients requiring hospitalization. Its alert also describes differing concentrations among compounded semaglutide products.1 Knowing these words is useful for a conversation with a pharmacist. It is not a reason to perform the conversion yourself.
An illustrative label map, without dose numbers
The following is an editorial example of fields to locate across the vial, pharmacy label and accompanying paperwork. Bracketed words are placeholders, not a real prescription, a legally complete label template or directions you can use.
Patient: [your name]. Pharmacy: [dispensing pharmacy and contact details]. Prescription identifier: [Rx number]. These fields help you confirm whose medicine it is and let the pharmacy find the dispensing record. If the patient name is wrong, contact the pharmacy before proceeding.
Medication: [ingredient or ingredients]. Concentration: [strength for each ingredient, with its measurement terms]. Quantity: [total liquid volume]. These describe the dispensed product. Ask the pharmacist to point out each field on your actual packaging, especially when a label has several ingredients or more than one strength expression. When the product description and FAQ list different ingredients, as in the Drip Hydration review, ask the pharmacist to confirm the full ingredient list on your prescription.
Directions: [the pharmacist-confirmed instructions for this prescription]. Supplies: [the syringe or device supplied]. Ask the pharmacist to explain how the written directions relate to those exact supplies. An online chart from a different pharmacy is not a substitute for that explanation.
Dates and handling: [beyond-use date], [storage instructions], [instructions after first puncture, if applicable], [lot or batch identifier, where provided]. Keep these with the medication. The purpose of this map is to make missing or ambiguous information visible before you need it.
If you are choosing a seller, our HealthRX review, our RxSpan MD review, and our yourEra review set out the prices, renewal terms and what we could not verify for each. All of these sellers pay us a commission when a reader signs up, which never changes a grade.
Ask the pharmacy to explain the dates together
A beyond-use date, often abbreviated BUD, is a limit assigned to the compounded preparation. USP's sterile-compounding FAQ defines the beyond-use date as the date and time after which a preparation must not be used.2 It is not an invitation to keep a vial indefinitely because some liquid remains.
FDA currently advises discarding compounded GLP-1 multidose vials within 28 days after first use, even if medication remains or the compounder provides a longer period.4 Ask the pharmacist how to record first use and identify any earlier discard requirement. A later printed BUD does not override this warning. This is separate from the storage instructions for a branded pen.
Storage instructions deserve the same attention at every refill. Empower Pharmacy's 2026 storage update, for example, tells patients with older lots to keep following the storage directions on those vial labels. It directs product questions to clinical staff.3 That illustrates why the current label matters; it does not establish a storage rule for all compounded GLP-1 medications. If a shipment's temperature is in question, follow our warm-shipment contact checklist.
For used supplies, see our pen and needle disposal guide.
Treat a refill as a new label check
Put the new packaging beside the previous packaging and identify any changes for the pharmacist: ingredient names, concentration, quantity, supplies, instructions, dates or dispensing pharmacy. Do not assume the familiar number on an older instruction sheet applies to the replacement vial. A step up in dose often arrives this way, and our dosage guide lists the starting doses and four-week steps the approved products follow, also without converting them to units. Ask the pharmacy to confirm which instructions are current and to correct conflicting documents.
This is particularly useful when switching GLP-1 providers. Tell the receiving practice what you actually have, using photographs of the label through its secure channel. Describing only a number of units omits the product information it needs to check your records.
A short message that makes the question answerable
Try: “Please review my prescription and these label photos. Can you identify the ingredient strength and total volume, confirm that the enclosed supplies match my written directions, and explain the storage and discard dates? The part I do not understand is [quote the exact wording]. Please send corrected written instructions if anything conflicts.”
Attach photographs of the vial label, pharmacy directions and supply packaging. Include the prescription number and your callback details. If the answer comes from a general customer-service agent and still leaves a medication question unresolved, request the dispensing pharmacist. Keep the response with the original paperwork so you are not relying on memory later.
A readable label does not establish FDA approval
Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness and quality before marketing in the way it reviews approved drugs.4 A neat label, a pharmacy logo or a longer BUD does not change that distinction.
Use compounded versus brand-name GLP-1 and our compounded semaglutide safety guide for the broader questions. For this particular vial, the useful endpoint is a pharmacist-confirmed explanation of the product and its directions. You should not have to guess your way from a label to an injection.
Frequently asked questions
Are mg, mL and syringe units interchangeable?
No. They describe different things. Ask the dispensing pharmacist to explain the concentration, prescribed directions and exact syringe together; do not substitute an online conversion chart.
Does a vial's beyond-use date tell me how long it lasts after puncture?
No. FDA advises discarding compounded GLP-1 multidose vials within 28 days after first use, even if the compounder allows longer. Ask the pharmacist about any earlier discard requirement and how to record first use.
What if my refill label differs from the previous vial?
Contact the dispensing pharmacist before using the refill. Ask which directions are current and have any conflict between the label, instruction sheet and supplies resolved.
References
- U.S. Food and Drug Administration (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. FDA. Read source
- United States Pharmacopeia (2023). USP <797> FAQs. USP. Read source
- Empower Pharmacy (2026). 2026 Storage Update. Empower Pharmacy. Read source
- U.S. Food and Drug Administration (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA. Read source
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Compounded Semaglutide and Tirzepatide Dosage: Starting Doses, Steps and Units
The FDA-label starting doses and step-ups for semaglutide and tirzepatide, why syringe units depend on your vial, and what to confirm with your pharmacist.
ReadHow Long Compounded Tirzepatide and Semaglutide Last: Fridge, Room Temperature and the 28-Day Rule
How long a compounded GLP-1 vial lasts in or out of the fridge depends on its own label. What the brand labels allow, and FDA's 28-day rule after first use.
ReadCompounded Tirzepatide Without a Membership: Sellers That Charge No Membership Fee
Sellers whose own pages say they charge no membership fee for compounded tirzepatide, split into pay-per-order and recurring plans, with prices and dates.
ReadGLP-1 Shipment Arrived Warm: What to Check Before Using It
Document a warm GLP-1 delivery, contact the dispensing pharmacy and understand why brand-specific storage allowances cannot clear a compounded shipment.
ReadGLP-1 Side Effects: What the Trials and FDA Labels Actually Report
The real side-effect data behind semaglutide and tirzepatide — GI rates, the boxed warning, gallbladder risk, retinopathy, and compounded-dosing errors.
ReadMissed a GLP-1 Dose? Separate a Late Injection From a Treatment Restart
Compare Wegovy injection and Zepbound missed-dose instructions, understand longer interruptions, and prepare the questions your prescriber needs to answer.
Read